Drugmakers signed deals worth at least $18 billion in combined value on Monday, the first day of the healthcare industry's ...

On Wall Street, shares of rivals Boston Beer, Molson Coors and Brown-Forman each dropped ... US pharmaceuticals group AbbVie ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra's primary pipeline ...

Serum level of inflammatory marker C-reactive protein (CRP) predicted response to adalimumab (Humira) treatment for patients ...

NEW YORK — Rheumatologists, dermatologists, drug manufacturers, and researchers do not pay enough attention to the role sex and gender play in the pathogenesis and presentation of psoriatic ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData, Phase III drugs for Short Bowel Syndrome have a 50% ...

The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer ...